Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody

Documenti analoghi

• The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus
  di: Eilat, Eran, et al.
  Pubblicazione: (2001)
• Characterization and role in experimental systemic lupus erythematosus of T-cell lines specific to peptides based on complementarity-determining region-1 and complementarity-determining region-3 of a pathogenic anti-DNA monoclonal antibody
  di: Brosh, N, et al.
  Pubblicazione: (2000)
• The Tolerogenic Peptide, hCDR1, Down-Regulates the Expression of Interferon-α in Murine and Human Systemic Lupus Erythematosus
  di: Sthoeger, Zev, et al.
  Pubblicazione: (2013)
• Methotrexate treatment in murine experimental systemic lupus erythematosus (SLE); clinical benefits associated with cytokine manipulation.
  di: Segal, R, et al.
  Pubblicazione: (1995)
• A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4(+)CD25(+) cells and TGF-β
  di: Sharabi, Amir, et al.
  Pubblicazione: (2006)